deCODE Clopidogrel™

Analyzes five SNPs in the CYP2C19 gene that affect response to the anti-platelet drug clopidogrel. This test identifies those who may need adjustment of their clopidogrel dose or who should be put on an alternative medication to prevent recurrent adverse cardiovascular events.

Personalizing therapy

How deCODE Clopidogrel™ can help.

Detecting carriers of reduced function alleles in the CYP2C19 gene identifies those who have decreased bioconversion of clopidogrel to its active metabolite and a decreased anti-platelet response. As a result, they may be at increased risk of recurrent adverse cardiovascular events despite their anti-platelet drug treatment.

The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for clopidogrel, informing health care providers of the availability of the CYP2C19 genetic test for the identification “poor metabolizers”, for whom other anti-platelet medications or alternative dosing strategies should be considered.

For information on indications, dosage, side effects and more, please refer to:

http://www.rxlist.com/plavix-drug.htm

This content was last reviewed on May 12, 2011.